Maya Skubatch
Partner
Maya Skubatch was a partner in the Palo Alto office of Wilson Sonsini Goodrich & Rosati and a former member of the firm’s board of directors. Maya focused on strategic patent counseling for both private and public life science companies. She worked closely with licensing, litigation, corporate, and regulatory counsel to provide integrated IP strategies and often assists clients with intellectual property matters pertaining to financings, M&A, and partnership deals. Maya also worked with investors on IP diligence matters.
Experience
Maya Skubatch was a partner in the Palo Alto office of Wilson Sonsini Goodrich & Rosati and a former member of the firm’s board of directors. Maya focused on strategic patent counseling for both private and public life science companies. She worked closely with licensing, litigation, corporate, and regulatory counsel to provide integrated IP strategies and often assists clients with intellectual property matters pertaining to financings, M&A, and partnership deals. Maya also worked with investors on IP diligence matters.
Education
- J.D., Santa Clara University School of LawIntern, Affymetrix, Inc.; Extern in the chambers of the Honorable Judge Susan Illston, U.S. District Court, Northern District of California
- B.A., Molecular and Cell Biology, University of California, BerkeleyConducted research in the laboratories of Howard Hughes Professor Randy Scheckman and Professor Sung-Ho Kim
Admissions
- State Bar of California
- Supreme Court of California
- U.S. District Court for the Central District of California
- U.S. District Court for the Eastern District of California
- U.S. District Court for the Northern District of California
- U.S. District Court for the Southern District of California
- U.S. Court of Appeals for the Federal Circuit
- U.S. Patent and Trademark Office
Credentials
Education
- J.D., Santa Clara University School of LawIntern, Affymetrix, Inc.; Extern in the chambers of the Honorable Judge Susan Illston, U.S. District Court, Northern District of California
- B.A., Molecular and Cell Biology, University of California, BerkeleyConducted research in the laboratories of Howard Hughes Professor Randy Scheckman and Professor Sung-Ho Kim
Admissions
- State Bar of California
- Supreme Court of California
- U.S. District Court for the Central District of California
- U.S. District Court for the Eastern District of California
- U.S. District Court for the Northern District of California
- U.S. District Court for the Southern District of California
- U.S. Court of Appeals for the Federal Circuit
- U.S. Patent and Trademark Office
Select Representations
- Day One Biopharmaceuticals in intellectual property matters related to its 2021 IPO and approval of OJEMDA™ (tovorafenib) in 2024
- Hexagon Bio in intellectual property matters through its $77 million Series B financing
- Thorne Research in inter partes reviews (IPRs) of US 8,383,086 US 8,197,807 related to nicotinamide riboside
- Progenity in inter partes review against Natera of six patents related to prenatal genetic testing
- Drawbridge in its spin out from GE and in developing its patents covering OneDraw™, a blood draw device that received FDA approval
- Labrys in developing patents covering fremanezumab (Ajovy™), a monoclonal antibody for the treatment of migraines, and its sale to Teva.
- Kythera in developing patents covering deoxycholic acid (Kybella™), currently an Allergan product
- Carmenta through its acquisition by Progenity for diagnosing pre-eclampsia
- Adverum in intellectual property matters related to its IPO and various follow-on offerings
- Verinata in intellectual property matters leading to its $425 million acquisition by Illumina
- Ion Torrent in intellectual property matters leading to its $725 million acquisition by Life Technologies
- Capp Medical in intellectual property matters relating to Avenio™ ctDNA testing and leading to its acquisition by Roche
Matters
Select Representations
- Day One Biopharmaceuticals in intellectual property matters related to its 2021 IPO and approval of OJEMDA™ (tovorafenib) in 2024
- Hexagon Bio in intellectual property matters through its $77 million Series B financing
- Thorne Research in inter partes reviews (IPRs) of US 8,383,086 US 8,197,807 related to nicotinamide riboside
- Progenity in inter partes review against Natera of six patents related to prenatal genetic testing
- Drawbridge in its spin out from GE and in developing its patents covering OneDraw™, a blood draw device that received FDA approval
- Labrys in developing patents covering fremanezumab (Ajovy™), a monoclonal antibody for the treatment of migraines, and its sale to Teva.
- Kythera in developing patents covering deoxycholic acid (Kybella™), currently an Allergan product
- Carmenta through its acquisition by Progenity for diagnosing pre-eclampsia
- Adverum in intellectual property matters related to its IPO and various follow-on offerings
- Verinata in intellectual property matters leading to its $425 million acquisition by Illumina
- Ion Torrent in intellectual property matters leading to its $725 million acquisition by Life Technologies
- Capp Medical in intellectual property matters relating to Avenio™ ctDNA testing and leading to its acquisition by Roche
Select Publications
- Co-author with H. Au, "Chapter 16: Patent Strategy – Patent Types and Considerations," Innovation in Nephrology, November 2024
- Co-author with D. Hoffmeister, C. Andres, D. Van Goor, and I. Dasgupta, "Dietary Supplements And FDA: Potential For Partnership?" Law360, March 7, 2018
- Co-author with D. Hoffmeister, V. Norviel, and C. Andres, "Complying with Expanded Access Policy Drug Laws," Law360, February 28, 2017
- Co-author, Brief for amici curiae Amarantus Bioscience Holdings, Inc., Exo Incubator, Inc., and Michael Heltzen in support of petitioner, Sequenom, Inc. v. Ariosa Diagnostics, Inc., et al., On Petition for a Writ of Certiorari to the United States Court of Appeals for the Federal Circuit, No. 15-1182
- Co-author, Brief for amici curiae Population Diagnostics, Inc., Avant Diagnostics, Inc., Personalis, Inc., Linda Bruzzone, and Erin Marie Mading in support of petitioner, Sequenom, Inc. v. Ariosa Diagnostics, Inc., et al., On Petition for a Writ of Certiorari to the United States Court of Appeals for the Federal Circuit, No. 15-1182
- Co-author, Brief of Amici Curiae Amarantus Bioscience Holdings, Inc., Personalis, Inc., and Population Diagnostics, Inc. in Support of Appellants' Petition for Rehearing En Banc, Ariosa Diagnostics, Inc. v. Sequenom, Inc., On Writ of Certiorari to the United States Court of Appeals for the Federal Circuit, No. 2014-1139, -1144
- Co-author, "A Novel Receptor for APO2L/Trail Contains a Truncated Death Domain," Current Biology, December 1, 1997
- Co-author, "TRAIL-Induced Apoptosis by a Family of Signaling and Decoy Receptors," Science 277, August 8, 1997
- Co-author, "Herpevirus Entry Mediator: A Member of the Tumor Necrosis Factor Receptor (TNFR) Family Interacts with Members of the Factors NF-kB and AP," Journal of Biological Chemistry, Vol. 296, May 30, 1997
Insights
Select Publications
- Co-author with H. Au, "Chapter 16: Patent Strategy – Patent Types and Considerations," Innovation in Nephrology, November 2024
- Co-author with D. Hoffmeister, C. Andres, D. Van Goor, and I. Dasgupta, "Dietary Supplements And FDA: Potential For Partnership?" Law360, March 7, 2018
- Co-author with D. Hoffmeister, V. Norviel, and C. Andres, "Complying with Expanded Access Policy Drug Laws," Law360, February 28, 2017
- Co-author, Brief for amici curiae Amarantus Bioscience Holdings, Inc., Exo Incubator, Inc., and Michael Heltzen in support of petitioner, Sequenom, Inc. v. Ariosa Diagnostics, Inc., et al., On Petition for a Writ of Certiorari to the United States Court of Appeals for the Federal Circuit, No. 15-1182
- Co-author, Brief for amici curiae Population Diagnostics, Inc., Avant Diagnostics, Inc., Personalis, Inc., Linda Bruzzone, and Erin Marie Mading in support of petitioner, Sequenom, Inc. v. Ariosa Diagnostics, Inc., et al., On Petition for a Writ of Certiorari to the United States Court of Appeals for the Federal Circuit, No. 15-1182
- Co-author, Brief of Amici Curiae Amarantus Bioscience Holdings, Inc., Personalis, Inc., and Population Diagnostics, Inc. in Support of Appellants' Petition for Rehearing En Banc, Ariosa Diagnostics, Inc. v. Sequenom, Inc., On Writ of Certiorari to the United States Court of Appeals for the Federal Circuit, No. 2014-1139, -1144
- Co-author, "A Novel Receptor for APO2L/Trail Contains a Truncated Death Domain," Current Biology, December 1, 1997
- Co-author, "TRAIL-Induced Apoptosis by a Family of Signaling and Decoy Receptors," Science 277, August 8, 1997
- Co-author, "Herpevirus Entry Mediator: A Member of the Tumor Necrosis Factor Receptor (TNFR) Family Interacts with Members of the Factors NF-kB and AP," Journal of Biological Chemistry, Vol. 296, May 30, 1997
Biological Sciences and Biotechnology
- Antibody
- Antigen presentation
- Biochemical assays
- Biochemistry
- Bioconjugation
- Biologics
- Cancer biology
- Cancer therapeutics
- CAR-T cells
- Cell biology
- Cell culture products
- Cell therapy
- Cellular biology
- Cellular immunology
- Genetics
- Genomics
- Immuno-oncology
- Immunobiology
- Immunology
- Metabolomics
- MicroRNA (miRNA) research
- Molecular biology
- Molecular genetics
- Neurobiology
- PCR
- Proteomics
- Stem cell biology
- T and B cell biology
- T cell biology
- T cell immunology
Therapeutics and Drug Discovery
- CRISPR
- Drug conjugates
- Drug delivery
- Gene editing
- Gene therapy
- Peptide therapeutics
- Pharmacodynamics
- Pharmacokinetics
- Pharmacology
- RNA interference (RNAi)
- Vaccines
Chemistry and Material Science
- Protein engineering
Engineering and Technology
- Microfluidics
Genomics and Data Analysis
- Bioinformatics algorithms
- Computational biology
- Next-generation sequencing
- Sequencing
- shRNA
Technical Fluency
Biological Sciences and Biotechnology
- Antibody
- Antigen presentation
- Biochemical assays
- Biochemistry
- Bioconjugation
- Biologics
- Cancer biology
- Cancer therapeutics
- CAR-T cells
- Cell biology
- Cell culture products
- Cell therapy
- Cellular biology
- Cellular immunology
- Genetics
- Genomics
- Immuno-oncology
- Immunobiology
- Immunology
- Metabolomics
- MicroRNA (miRNA) research
- Molecular biology
- Molecular genetics
- Neurobiology
- PCR
- Proteomics
- Stem cell biology
- T and B cell biology
- T cell biology
- T cell immunology
Therapeutics and Drug Discovery
- CRISPR
- Drug conjugates
- Drug delivery
- Gene editing
- Gene therapy
- Peptide therapeutics
- Pharmacodynamics
- Pharmacokinetics
- Pharmacology
- RNA interference (RNAi)
- Vaccines
Chemistry and Material Science
- Protein engineering
Engineering and Technology
- Microfluidics
Genomics and Data Analysis
- Bioinformatics algorithms
- Computational biology
- Next-generation sequencing
- Sequencing
- shRNA
Recent Insights
Client Highlights
Wilson Sonsini Advises SonoThera on Patent Matters Related to Oversubscribed $125 Million Series B
On June 10, 2026, SonoThera, a biotechnology company developing next-generation genetic medicines to address the root causes of disease, announced the closing of an oversubscribed $125 million Series B financing round to advance its lead programs in Duchenne muscular dystrophy (DMD) and autosomal dominant polycystic kidney disease (ADPKD) into the clinic and expand its pipeline of targeted, redosable genetic medicines. Wilson Sonsini Goodrich & Rosati advised SonoThera on patent matters related to the transaction.
Learn More
Client Highlights
Wilson Sonsini Advises Excellergy on $2 Billion Acquisition by Novartis
On March 27, 2026, Excellergy, a biotechnology company developing a novel class of allergy therapeutics, announced it will be acquired by Novartis in a transaction with a total potential value of up to $2 billion in upfront and milestone payments. The acquisition brings together Excellergy's novel trifunctional ECRIs with the development expertise of Novartis. Wilson Sonsini Goodrich & Rosati advised Excellergy on the transaction.
Learn More
Recent Events
Affiliated Programs
Biotech CEO Summit 2025
Wilson Sonsini is proud to sponsor the Biotech CEO Summit in Napa, the premier conference designed exclusively for CEOs in the life science industry. The Summits focus on the participating CEOs discussing issues of importance to them as leaders of companies they want to position for growth and success. The Summits are discussion based meetings led by subject matter experts. All participants are invited to, and indeed encouraged to join the discussions by asking questions and sharing their personal insights. The Summits are run under Chatham House Rules to encourage open and frank conversation.
Learn More
- Privacy Policy
- Terms of Use
- Accessibility
Copyright © 2026 Wilson Sonsini Goodrich & Rosati. All Rights Reserved.